Erlinda Maria Gordon
Erlinda Maria Gordon, M.D. Sarcoma Oncology Research Center, USA
Biography
Erlinda M. Gordon, M.D. is a Diplomate of the American Board of Pediatrics, Pediatric Hematology/Oncology, Director, Biological and Immunological Therapies, Sarcoma Oncology Research Center, Santa Monica CA, Chairman, Institutional Biosafety Committee, Sarcoma Oncology Research Center, Santa Monica CA, Principal Investigator, Phase 1/2 study using Trabectedin, Ipilimumab and Nivolumab as first line therapy for soft tissue sarcoma and Co-investigator of over 20 Phase I-III clinical trials using targeted therapies. She is Co-Inventor of >200 patents/patent applications, and Founder of 2 biotech companies, Counterpoint Biomedica LLC, whose mission is to develop (1) tumor targeted bifunctional polypeptides that bond non-covalently with drugs (2) biomarkers for the identification and capture of circulating tumor cells, and (3) tumor-targeted recombinant human GM-CSF for cancer immunotherapy, and Epeius Biotechnologies Corp., whose mission is to develop targeted gene therapy vectors for cancer (Rexin-G) and cancer immunotherapy (Reximmune-C). She was a Tenured Associate Professor, USC Keck School of Medicine.
Abstract
Abstract : Combinatorial Chemo-/Immunotherapy for Soft Tissue Sarcoma